GANX Share Price Performance
US$2.12
0.38 (21.84%)
72.1% undervalued intrinsic discount
US$7.60
Fair Value
Price US$2.12
Lou_Basenese US$7.60
Fair ValueUS$7.60
Share Pricen/a
Gain Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 2 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
GANX Community Narratives
LO
Fair Value US$7.6 72.1% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
20users have liked this narrative
2users have commented on this narrative
41users have followed this narrative
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
3.2k
users have viewed this narrative20users have liked this narrative
2users have commented on this narrative
41users have followed this narrative
LO
US$7.6
72.1% undervalued intrinsic discount
Fair Value
Profit Margin
18.91%
Future PE
25.12x
Price in 2031
US$10.68
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Gain Therapeutics, Inc. Key Details
About GANX
- Founded
- 2017
- Employees
- 21
- CEO
- WebsiteView website
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
